AbbVie (NYSE: ABBV) today announced that JAMA Dermatology has published 24-week results from the Phase 3b Heads Up study evaluating the efficacy and safety of RINVOQ® (upadacitinib, 30 mg, once daily) versus DUPIXENT® (dupilumab, 300 mg, every other week) – both as monotherapy treatments – in adults with moderate to severe atopic dermatitis who were candidates for systemic therapy.
You might think that any stock handpicked by Warren Buffett and his top investment managers would be held in high regard by most investors. Several stocks in Berkshire Hathaway's (NYSE: BRK.A) (NYSE: BRK.B) portfolio are either beaten down, have bargain valuations, or both. Here are three underrated Buffett stocks that are smart buys right now.
ABBV earnings call for the period ending June 30, 2021.